11 results about "Peripheral Blood Stem Cells" patented technology

The present invention relates to a method for amplifying an invariant natural killer T (iNKT) population and an application thereof, the method comprising: providing a peripheral blood stem cell sample; culturing the peripheral blood stem cell sample in an amplification culture medium, wherein the amplification culture medium comprises interleukin 2, interleukin 15 and alpha-galactosylceramide; and adjusting the number of the cultured cells, and co-culturing the cultured cells and feeder cells in the amplification medium, the feeder cells being a dendritic cell and a peripheral blood mononuclear cell.

The utility model relates to the technical field of medical instruments, in particular to a screening and filtering device for peripheral blood stem cells. The filter comprises a filter body, a filter frame is installed in the filter body, an adjusting device is arranged on the arc surface of the filter body, the adjusting device comprises a fixing plate, the fixing plate is fixedly connected with the arc surface of the filter body, and four adjusting plates are fixedly connected to the lower surface of the fixing plate. The surfaces of the four adjusting plates are slidably connected with adjusting bins, one sides of the four adjusting bins are fixedly connected with stabilizing plates, and one sides of the adjusting bins are fixedly connected with fixing rods. The problems that when a worker sits on a chair to use a filter body, due to the fact that some workers are too tall or too short, when the worker sits on the chair to use the filter body, the worker is difficult to use the filter body in the most comfortable posture, and the working efficiency of the worker is affected are solved.

The present invention relates to a method for mass-producing immunosuppressive T cells using human serum albumin. According to the present invention, when peripheral blood stem cells (PBSCs) obtained from individuals administered with granulocyte colony-stimulating factor (G-CSF) are cultured in a medium containing human serum albumin (HSA) or HSA and mercaptoethanol, immunosuppressive T cells having immunosuppressive effects can be mass-produced. It has been confirmed that the immunosuppressive T cells exhibit excellent therapeutic effects against acute graft-versus-host disease. Therefore, the present invention is expected to be useful in the treatment of immune diseases such as acute graft-versus-host disease.

A method for inducing and activating a conventional dendritic cell subset, the method comprising the following steps: A. seeding human peripheral blood stem cells or umbilical cord blood stem cells in a plate, and performing expansion culture using a basal medium supplemented with cytokine 1; B. performing in vitro induced differentiation culture on the cells after the expansion culture using a basal medium supplemented with cytokine 2; C. sorting the differentiated cells to obtain pure cDC1 cells; and D. performing activation culture on the pure cDC1 cells using a basal medium supplemented with a stimulator to obtain activated cDC1 cells. A large number of human primary cDC1 are obtained by means of induction from umbilical cord blood stem cells, and the anti-tumor ability of cDC1 is then activated by means of a combination of stimulators. Moreover, the feasibility and efficacy of cDC1 for tumor therapy are verified for the first time by means of a humanized mouse tumor model.

Blood in a separation chamber is separated into a red blood cell layer, a plasma constituent, and a mononuclear cell-containing layer. A portion of the plasma constituent exits the chamber via a plasma outlet, while a first portion of the red blood cell layer exits via a red blood cell outlet. A second portion of the red blood cell layer exits the chamber via the red blood cell outlet and is collected. At least a portion of the collected red blood cell layer may then be conveyed to the chamber via the red blood cell outlet to convey at least a portion of the mononuclear cell-containing layer out of the chamber via the plasma outlet for collection. A second portion of the plasma constituent may be conveyed out of the chamber via the plasma outlet to more fully collect the mononuclear cell-containing layer without the use of collected plasma.

Disclosed herein is a method for producing mature dendritic cells from peripheral blood mononuclear cells (PBMCs). The method includes the steps of, treating the PBMCs with a cultivating medium supplemented with interleukin 4 (IL-4) and granulocyte-macrophage colony-stimulating factor (GM-CSF) to produce immature dendritic cells; and then treating the immature dendritic cells with the cultivating medium supplemented with IL-4, GM-CSF, tumor necrosis factor alpha (TNF-α), and Prostaglandin E2 (PGE2) to produce the mature dendritic cells. According to embodiments of the present disclosure, the PBMCs used in the present method are isolated from a leukocyte concentrate or a cryopreserved peripheral blood stem cells (PBSCs) stock.

The objective of the present invention is to provide a method for effectively isolating and proliferating stem cells from the peripheral blood. A composition according to the present invention comprises interferon-gamma (IFN-γ) so as to increase the adhesion of stem cells isolated from the peripheral blood, and thus increases acquisition yield of the stem cells. Therefore, the composition and the peripheral blood-derived stem cell isolation and culture method, according to the present invention, are established and used to induce differentiation into progenitor cells, which can be differentiated into somatic cells of various target tissues, and are used for prevention or treatment of diseases.

The invention relates to a method for mass production of immunosuppressive T cells by using human serum albumin. According to the present invention, it is confirmed that when a peripheral blood stem cell (PBSC) obtained from an individual administered with a granulocyte colony stimulating factor (G-CSF) is cultured in a culture medium containing human serum albumin (HSA) or HSA and mercaptoethanol, an immunosuppressive T cell having an immunosuppressive effect can be produced in a large scale, and the immunosuppressive T cell having an immunosuppressive effect can be produced in a large scale. The immunosuppressive T cell shows an excellent acute graft-versus-host disease treatment effect, so that the immunosuppressive T cell is expected to be effectively applied to treatment of immune diseases such as acute graft-versus-host diseases.